Unbiased and Practical Psychopharmacology Updates

Get exclusive psychopharmacology updates. Earn up to 155 CMEs, including 40 SA CMEs credits.

Explore Memberships

Receive psychopharmacology updates in your inbox

TRENDING IN PSYCHOPHARMACOLOGY INSTITUTE

Quick Takes

The latest research that matters to your practice. CME available.

Switching Oral Antipsychotics: Six Strategies and Tips

Benzodiazepine Tapering: Key Takeaways From New Guidelines

Deprescribing Antipsychotics Post-Delirium: Why It Matters

Is Ondansetron Effective for Negative Symptoms in Schizophrenia?

Lithium Orotate: Breakthrough Treatment for Alzheimer’s Disease?

View All

Brain Guides

Guides distilling the literature for confident prescribing. CME available.

Tricyclic Antidepressants in Psychiatry: Selection and Prescribing

Serotonin Syndrome: Mechanisms, Diagnosis, High-Risk Interactions, and Management

Antidepressants and Metabolic Disturbances

Gastrointestinal Side Effects of Antidepressants: Mechanisms, Comparison and Management Strategies

View All

Video Lectures

A selection of practical sections from our video lectures. CME available for Bronze, Silver, and Gold members.

Initiating and Optimizing Clozapine

Treating Anxiety Disorders in Patients With Cancer

Prevalence, Assessment, and Management of RBD

Considerations for Using Benzodiazepines and Benzodiazepine Receptor Agonists in the Geriatric Population

Use of Omega-3 Fatty Acids in Children and Adolescents

View All

RECENT PUBLICATIONS

Gepirone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

0.50 CMEs
This guide examines gepirone, the first FDA-approved selective 5-HT1A receptor agonist for major depressive disorder; its favorable sexual side-effect profile and weight neutrality, dose-dependent QTc prolongation requiring ECG monitoring, mandatory food administration, and contraindication with strong CYP3A4 inhibitors. It also traces gepirone’s unusually contested path to approval — four FDA rejections and a 2015 advisory-committee vote against its efficacy before the FDA approved it in 2023 on a modest evidence base.
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Quick Take Vol. 88

0.75 CMEs
Must antipsychotics always be avoided in catatonia? Should you prescribe antidepressants in bipolar depression? Should clozapine start after just one failed antipsychotic trial? Is atypical depression a distinct subtype that resists standard antidepressants? Does soft drink intake worsen depression?
Faculty: Scott R. Beach, M.D., James Phelps, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D., Paul Zarkowski, M.D.
38.52 minutes in 5 audio sections

Antipsychotic Blood Levels: Why and How – Interview

0.50 CMEs
A discussion with Dr. John Kane on therapeutic drug monitoring of antipsychotics, covering proper sampling timing, distinguishing pseudo-resistance from true treatment resistance, the clozapine TDM algorithm and smoking effects, drug-specific monitoring of risperidone, aripiprazole, and haloperidol, long-acting injectables, and use in pregnancy.
John M. Kane, M.D.
Zucker Hillside Hospital & Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
28.22 minutes of audio interview

Highlights from ASCP 2026 – Clinical Pearls in Psychopharmacology

0.50 CMEs
This guide distills practical pearls from the 2026 ASCP Annual Meeting: deprescribing complex regimens by reconstructing each drug’s purpose (“pharmacoarcheology”); interpreting what “FDA approval” does and does not mean; tailoring antipsychotic choice and dose to ancestry and metabolism (benign ethnic neutropenia and clozapine access, first-trimester safety); and montelukast’s age-stratified neuropsychiatric effects.
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Prescribing Psychotropics in Medically Complex Patients: What Clinicians Need to Know

1.25 CMEs
A guide to safe prescribing in patients with cardiovascular disease, anticoagulation requirements, and renal failure. Dr. Gee reviews the cardiac risk profile of ADHD medications, antidepressant and antipsychotic interactions with anticoagulants, mood stabilizer management in patients on NOACs and warfarin, antidepressant and antipsychotic dosing in hemodialysis, and alternative administration routes for patients who cannot take oral medications.
Siobhan Gee, M.Pharm., P.G.Dip., M.R.Pharm.S., Ph.D.
South London and Maudsley NHS Foundation Trust
79.49 minutes in 10 sections

Quick Take Vol. 87

0.50 CMEs
Which antipsychotic should you choose for a woman with first-episode psychosis? When clozapine isn’t an option for treatment-resistant schizophrenia, what actually works? Do real-world abuse data change how you select insomnia medications? Did serial ketamine outperform midazolam in a new inpatient trial? Can sustained anthocyanin intake improve cognition?
Faculty: Amanda Koire, M.D., Ph.D., Oliver Freudenreich, M.D., F.A.C.L.P., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., James Phelps, M.D., Derick E. Vergne, M.D.
33.59 minutes in 5 audio sections

Explore our library of over 480 video lectures, podcasts, research summaries, and expert interviews.

Explore Our Library

CME Information

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

Lost as a newly-matched psychiatry resident?

Access ALL our products FREE for 3 months!

Get Instant Access